Allarity Therapeutics Announces JPO Grant of Key DRP Companion Diagnostic Patent

What Happened
Allarity Therapeutics, Inc. announced on September 15, 2026 (disclosed in an 8‑K filed September 16, 2026) that the Japan Patent Office has granted a key patent covering the company’s proprietary stenoparib‑specific Drug Response Predictor (DRP®) companion diagnostic. The company attached a press release describing the grant as Exhibit 99.1 to the Form 8‑K.

Key Details

• Date announced: September 15, 2026; Form 8‑K filed September 16, 2026.
• Issuing authority: Japan Patent Office (JPO) granted the patent.
• Scope: Patent covers Allarity’s stenoparib‑specific DRP® companion diagnostic.
• Disclosure: Press release attached as Exhibit 99.1 to the 8‑K.

Why It Matters
A granted patent in Japan strengthens Allarity’s intellectual property position for its DRP companion diagnostic tied to stenoparib in that market. Patents provide legal protection for proprietary diagnostics and can be an important asset in commercialization, collaborations, or licensing discussions tied to the company’s therapeutic programs. Investors should note the patent grant as an IP milestone; the 8‑K serves to inform the market of this development.